Stock Markets

Daily coverage of equity markets, sectors, and major indices.

In-depth reporting on U.S. and global stock markets, including index performance, sector rotation, earnings reactions, volatility trends, and notable single-stock moves. Designed to help traders and investors understand what is driving price action across equities.

Articles

1,545 total articles

Beamr Shares Tick Up Ahead of Mile High Video 2026 Validation Demo

Beamr Shares Tick Up Ahead of Mile High Video 2026 Validation Demo

Beamr Imaging Ltd. (NASDAQ: BMR) saw its shares rise 2% in premarket trade as the video optimization firm prepares to present a three-layer validation framework at Mile High Video 2026 in Denver. The system combines a real-time AI upscaler, a patented Content-Adaptive Bitrate tool, and a human-aligned quality verification layer to help broadcasters…

London market slips as earnings season weighs; pound steadies above $1.37

London market slips as earnings season weighs; pound steadies above $1.37

UK blue chips fell on Wednesday as investors processed corporate earnings and guidance updates. The FTSE 100 dipped 0.5% while the pound eased 0.4% to 1.3786 against the dollar. Broader European markets were lower, led by luxury names after LVMH signalled caution despite modest quarterly sales growth. A range of UK-listed companies from retail to m…

Kepler Lowers Boliden to Hold, Cites Limited Upside After Rally

Kepler Lowers Boliden to Hold, Cites Limited Upside After Rally

Kepler Cheuvreux has downgraded Boliden to Hold from Buy ahead of the miner's fourth-quarter results, citing constrained upside after a significant share-price rally even as the broker raised its target price to SEK 640. The analyst lifted metal price assumptions and pushed up earnings estimates, while forecasting Q4 2025 EBIT excluding process inv…

REGENXBIO Shares Plunge After FDA Freezes Two Gene Therapy Trials

REGENXBIO Shares Plunge After FDA Freezes Two Gene Therapy Trials

REGENXBIO Inc. shares dropped 28% Wednesday after U.S. regulators placed clinical holds on two of the biotech's investigational gene therapies for ultra-rare pediatric disorders. The action stems from the identification of a brain tumor in a child treated with RGX-111 four years earlier; preliminary analysis found an AAV vector genome integration e…

MSCI Posts Higher Q4 Profit as Clients Flock to Indexes and Analytics

MSCI Posts Higher Q4 Profit as Clients Flock to Indexes and Analytics

MSCI reported stronger adjusted profit for the quarter ended December 31, driven by increased client spending on its index products and analytics services. Asset-based fees rose, lifting overall revenue, while operating costs grew more modestly as the company invested in staff and technology. Management highlighted continued multi-year growth in ad…

Wix Board Greenlights $2 Billion Buyback; Shares Jump on Announcement

Wix Board Greenlights $2 Billion Buyback; Shares Jump on Announcement

Wix.com Ltd. shares rose sharply after the company’s board approved a $2 billion share repurchase program spanning fiscal years 2026-2027. The authorization permits purchases of ordinary shares and convertible notes via open market and private transactions, to be funded by cash on hand, operating cash flow, or potentially new capital. The program i…

Birkenstock Seeks €1 Billion in New Revenue Over Next Three Years

Birkenstock Seeks €1 Billion in New Revenue Over Next Three Years

Birkenstock has set a target of generating 1 billion euros in incremental revenue across the next three years, aiming for annual top-line growth of 13%-15% at constant currencies. The company expects double-digit expansion in the Americas and EMEA, a doubling of its Asia-Pacific business, and adjusted EPS to grow about 200 basis points faster than …

UBS Lowers Rating on Mobimo to Sell, Cites Peak Development Earnings in FY25

UBS Lowers Rating on Mobimo to Sell, Cites Peak Development Earnings in FY25

UBS cut its rating on Swiss property owner Mobimo to sell from neutral, saying the company’s development profits - a key earnings driver - should peak in fiscal 2025 and then decline as high-margin projects complete. The broker raised its 12-month price target to CHF330 from CHF308 after lowering its WACC and modestly raising revenue forecasts, but…